Mixed Lineage Kinase Suppression in Triple-Negative Breast Cancer: Identification of a Dual Inhibitor Targeting MLK3...

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies.
• Mixed lineage kinase 3 (MLK3) is implicated in TNBC progression.
• Nicotinamide phosphoribosyltransferase (NAMPT) is upregulated in TNBC to meet NAD+ demands.

Purpose of the Study:

• To develop a novel dual inhibitor targeting both MLK3 and NAMPT for enhanced TNBC therapy.
• To evaluate the efficacy and immunomodulatory effects of the dual inhibitor GR2-128.

Main Methods:

• Design and optimization of GR2-128 using cell-free and cell-based assays.
• Assessment of GR2-128's antiproliferative activity in TNBC cell lines.
• In vivo studies in a syngeneic mouse breast cancer model.

Main Results:

• GR2-128 demonstrated matched nanomolar inhibition of MLK3 and NAMPT.
• GR2-128 exhibited antiproliferative effects in TNBC cell lines with favorable pharmacokinetics.
• In vivo, GR2-128 reduced tumor growth, increased apoptosis, modulated immune cell infiltration, and enhanced tumor T-cell markers.

Conclusions:

• Dual inhibition of MLK3 and NAMPT is a viable therapeutic strategy for TNBC.
• GR2-128 shows potential for TNBC treatment and tumor immuno-sensitization.